These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639 [TBL] [Abstract][Full Text] [Related]
5. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse. Sun W; Shi Y; Lee WC; Lee SY; Long F Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446 [TBL] [Abstract][Full Text] [Related]
6. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894 [TBL] [Abstract][Full Text] [Related]
7. Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms. Chandra A; Lin T; Young T; Tong W; Ma X; Tseng WJ; Kramer I; Kneissel M; Levine MA; Zhang Y; Cengel K; Liu XS; Qin L J Bone Miner Res; 2017 Feb; 32(2):360-372. PubMed ID: 27635523 [TBL] [Abstract][Full Text] [Related]
9. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737 [TBL] [Abstract][Full Text] [Related]
10. Early response of bone marrow osteoprogenitors to skeletal unloading and sclerostin antibody. Shahnazari M; Wronski T; Chu V; Williams A; Leeper A; Stolina M; Ke HZ; Halloran B Calcif Tissue Int; 2012 Jul; 91(1):50-8. PubMed ID: 22644321 [TBL] [Abstract][Full Text] [Related]
11. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats. Nioi P; Taylor S; Hu R; Pacheco E; He YD; Hamadeh H; Paszty C; Pyrah I; Ominsky MS; Boyce RW J Bone Miner Res; 2015 Aug; 30(8):1457-67. PubMed ID: 25678055 [TBL] [Abstract][Full Text] [Related]
12. Myeloid Lineage Ablation of Karkache IY; Damodaran JR; Molstad DHH; Mansky KC; Bradley EW Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575866 [TBL] [Abstract][Full Text] [Related]
13. Roles of Wnt signals in bone resorption during physiological and pathological states. Maeda K; Takahashi N; Kobayashi Y J Mol Med (Berl); 2013 Jan; 91(1):15-23. PubMed ID: 23111637 [TBL] [Abstract][Full Text] [Related]
14. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. van Dinther M; Zhang J; Weidauer SE; Boschert V; Muth EM; Knappik A; de Gorter DJ; van Kasteren PB; Frisch C; Mueller TD; ten Dijke P PLoS One; 2013; 8(4):e62295. PubMed ID: 23638027 [TBL] [Abstract][Full Text] [Related]
15. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration. Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG Bone; 2021 Feb; 143():115708. PubMed ID: 33164872 [TBL] [Abstract][Full Text] [Related]
16. Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts. Koide M; Kobayashi Y; Yamashita T; Uehara S; Nakamura M; Hiraoka BY; Ozaki Y; Iimura T; Yasuda H; Takahashi N; Udagawa N J Bone Miner Res; 2017 Oct; 32(10):2074-2086. PubMed ID: 28543818 [TBL] [Abstract][Full Text] [Related]
17. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis. Cai X; Xing J; Long CL; Peng Q; Humphrey MB J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106 [TBL] [Abstract][Full Text] [Related]
18. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. Hesse E; Schröder S; Brandt D; Pamperin J; Saito H; Taipaleenmäki H JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30965315 [TBL] [Abstract][Full Text] [Related]
19. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes. Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454 [TBL] [Abstract][Full Text] [Related]
20. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin. Mendoza-Villanueva D; Zeef L; Shore P Breast Cancer Res; 2011 Oct; 13(5):R106. PubMed ID: 22032690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]